OptiBiotix Health Plc Stock price

Equities

OPTI

GB00BP0RTP38

Biotechnology & Medical Research

Market Closed - London S.E. 12:35:01 2024-03-28 pm EDT 5-day change 1st Jan Change
19.6 GBX -6.67% Intraday chart for OptiBiotix Health Plc -20.00% -26.73%
Sales 2021 2.21M 2.79M Sales 2022 457K 576K Capitalization 12.08M 15.23M
Net income 2021 6M 7.56M Net income 2022 2M 2.52M EV / Sales 2021 17.7 x
Net cash position 2021 1.19M 1.5M Net cash position 2022 1.05M 1.33M EV / Sales 2022 24.1 x
P/E ratio 2021
7.02 x
P/E ratio 2022
4.77 x
Employees 9
Yield 2021 *
-
Yield 2022
-
Free-Float 86.67%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.57%
1 week-14.78%
Current month-21.94%
1 month-16.48%
3 months-20.46%
6 months-24.76%
Current year-21.94%
More quotes
1 week
20.50
Extreme 20.5
25.00
1 month
20.50
Extreme 20.5
29.33
Current year
20.50
Extreme 20.5
30.00
1 year
5.57
Extreme 5.57
43.50
3 years
5.57
Extreme 5.57
58.00
5 years
5.57
Extreme 5.57
89.85
10 years
5.57
Extreme 5.57
133.25
More quotes
Managers TitleAgeSince
Founder 64 06-06-18
Director of Finance/CFO 61 Nov. 30
Director/Board Member - 14-11-17
Members of the board TitleAgeSince
Chairman 72 17-12-31
Director/Board Member 66 18-09-09
Founder 64 06-06-18
More insiders
Date Price Change Volume
24-03-28 19.6 -6.67% 569 762
24-03-27 21 0.00% 109,092
24-03-26 21 0.00% 158,969
24-03-25 21 -11.58% 915,617
24-03-22 23.75 -3.06% 200,206

Delayed Quote London S.E., March 28, 2024 at 04:31 am EDT

More quotes
OptiBiotix Health Plc is a United Kingdom-based life sciences company. The Company is primarily engaged in identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry segment. Its technology platforms include OptiBiome, OptiScreen and OptiBiotic. Its OptiBiome technology platform that screens identifies and/or develops microbiome modulators, which can be used in formulations to prevent, manage and a range of chronic lifestyle diseases. The OptiScreen pharmaceutical screening platform to identify microbial metabolic pathways that interact with human pathways to improve health. The OptiBiotic platform generates oligosaccharides and screens them for their ability to modulate specific microbial genera or species and their microbial end products (short chain fatty acids, such as acetate, propionate, butyrate) and physical properties (sweetness). Its products include SlimBiome, SweetBiotix, CholBiome, SlimBiome Medical and WellBiome.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock OptiBiotix Health Plc - London S.E.